News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kamada Ltd. (KMDA.TA) Announces Successful Interim Report of the Phase 2-3 Clinical Trial with its Inhaled Alpha-1 Antitrypsin


2/14/2011 8:14:27 AM

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES